Clinical study of the effect of Wen Yang Yi QI on the quality of life of patients with breast cancer after operation

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-15007492

Enrollment

Unknown

Registered

2015-12-01

Start date

2014-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

test group:WenYangYi Qi Fang

Control group:Placebo

Eligibility

Sex/Gender

Female

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Modified radical mastectomy for breast cancerClinical stage II - IVmore than one month after radiotherapy and chemotherapy; 2. ER(+)Oral third generation aromatase inhibitors; 3. Chinese medicine of Yang Qi Deficiency Patients; 4. Postmenopausal women and age =60 points; 6. Elevated levels of serum lipids or estrogen levels, or overweight.

Exclusion criteria

Exclusion criteria: 1. Breast cancer without surgical treatment; 2. TCM is not Yang Deficiency; 3. KPS75 years; 5. Patients with severe heart, lung, liver, kidney disease and mental disease; 6. Patients are using other drugs that affect the trial of the subject.

Design outcomes

Primary

Measure	Time frame
The third generation aromatase inhibitor side effects scale;SF-36;FACT-B;	—

Secondary

Measure	Time frame
Lipid levels;Estrogen level;	—

Countries

China

Contacts

Public ContactYang Cao

13681050363@163.com+86 13681050363

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026